<DOC>
	<DOCNO>NCT01889849</DOCNO>
	<brief_summary>This research protocol `` Comparative pharmacokinetics pharmacodynamics peginterferon Bacterial Intravenous Protein 48 kilodaltons ( BIP48 ) 40 kilodaltons ( 40kDa ) healthy volunteer . '' This Phase I clinical trial compare pharmacokinetic pharmacodynamic parameter , safety two product : peginterferon alfa-2a ( PEGASYS ® ) BIP48 . It double-blind , randomize crossover rest period ( wash-out ) 4 week . The study population 32 healthy male volunteer administer single dose 180 microgram product , subcutaneously . The study total duration 14 day treatment step . The serum concentration PEG-interferon product , measure enzyme immunoassay ( EIA ) antiviral activity PEG-interferon , main variable.For purpose 15 sample volunteer need . Clinical laboratory variable , useful pharmacodynamics parameter Beta-2 microglobulin ( β2M ) - 2 ' 5'oligoadenylate synthetase - oligoadenylate synthetase ( OAS ) - neopterin ) safety evaluation , measure .</brief_summary>
	<brief_title>Comparative Pharmacokinetics Pharmacodynamics Peginterferon BIP48 40kDa Healthy Volunteers</brief_title>
	<detailed_description>Double-blind study , ie , volunteer study team aware product administer . As presentation two product different , professional administer injection blind , contact volunteer member study team apply medication .</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>No history chronic disease ; Preserved oral health ; No history acute illness last 30 day ; Absence significant clinical symptom sign physical examination ; laboratory test within normal limit ; image test within normal limit ; Seronegative test HIV B C Hepatitis ; Signing consent form ; Male ; Age 18 35 year ; Body mass index 19 26 ( weight kg / height meter square ) . Patients hypersensitivity Interferon alpha , Escherichia coliderived product , polyethylene glycol ( macrogol ) , constituent salt preparation . Individuals treat type interferon time , prior present research . History chronic disease autoimmune disease , liver failure , decompensated cirrhosis , heart disease , renal failure , diabetes mellitus , thyroid disease , hemoglobinopathy , cytopenia , history psychiatric disease , retinopathy , optic neuritis . History acute viral disease last 30 day ; Current use medication alter immunity : corticosteroid , immunosuppressant ; History know allergy drug , include interferon component product ( discretion investigator ) ; Having undergone surgery 6 month prior study entry ; Had donate blood three month prior study entry ; History alcoholism current use alcohol ; Use illicit drug past 6 month ; Participation clinical study previous therapeutic intervention year prior inclusion .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>